ABBOTT INDIA LIMITED (Rs. in Crores)
Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or | ||||||||||||||||||||||
investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was | ||||||||||||||||||||||
undertaken. | ||||||||||||||||||||||
In case monies are due to either | In case any financial indebtedness is incurred to make or | |||||||||||||||||||||
Details of the party (listed entity | party as a result of the | |||||||||||||||||||||
Details of the counter party | give loans, inter-corporate deposits, advances or | Details of the loans, inter-corporate deposits, advances or investments | ||||||||||||||||||||
/subsidiary) entering into the transaction | transaction | |||||||||||||||||||||
investments | ||||||||||||||||||||||
Value of the | ||||||||||||||||||||||
Type of related party | Detail of other related | related party | Remarks on | Value of transaction | Purpose for | |||||||||||||||||
Sr. No. | transaction as | approval by audit | during the reporting | Notes | ||||||||||||||||||
transaction | party transaction | Nature (loan/ | which the | |||||||||||||||||||
approved by the | committee | period | Nature of | |||||||||||||||||||
Relationship of the | advance/ | funds will be | ||||||||||||||||||||
audit committee | Opening | indebtedness | ||||||||||||||||||||
counterparty with the | Closing Balance | Details of other | Cost | inter- | Interest | Secured/ | utilised by the | |||||||||||||||
Name | PAN | Name | PAN | balance as on | (loan/ issuance of | Tenure | Tenure | |||||||||||||||
listed entity or its | as on 31.03.23 | indebtedness | corporate | Rate (%) | unsecured | ultimate | ||||||||||||||||
subsidiary | 01.10.22 | debt/ any other | deposit/ | recipient of | ||||||||||||||||||
etc.) | ||||||||||||||||||||||
investment | funds (end- | |||||||||||||||||||||
usage) | ||||||||||||||||||||||
1 | Abbott India Limited | AAACB5170B | Anisha Motwani | ZZZZZ9999Z | Independent Director | Director's Sitting Fees | Director's Sitting Fees | NA | Approved | 0.07 | 0 | 0 | - | |||||||||
2 | Abbott India Limited | AAACB5170B | Kaiyomarz Marfatia | ZZZZZ9999Z | Non-Executive Director | Director's Sitting Fees | Director's Sitting Fees | NA | Approved | 0.04 | 0 | 0 | - | |||||||||
3 | Abbott India Limited | AAACB5170B | Munir Shaikh | ZZZZZ9999Z | Non-Executive Director | Director's Sitting Fees | Director's Sitting Fees | NA | Approved | 0.06 | 0 | 0 | - | |||||||||
4 | Abbott India Limited | AAACB5170B | Shalini Kamath | ZZZZZ9999Z | Independent Director | Director's Sitting Fees | Director's Sitting Fees | NA | Approved | 0.07 | 0 | 0 | - | |||||||||
5 | Abbott India Limited | AAACB5170B | Sudarshan Jain | ZZZZZ9999Z | Independent Director | Director's Sitting Fees | Director's Sitting Fees | NA | Approved | 0.06 | 0 | 0 | - | |||||||||
6 | Abbott India Limited | AAACB5170B | Vivek V Kamath | ZZZZZ9999Z | KMP - Managing Director | Key Management | Key Management | NA | Approved | 4.68 | 0 | 0 | - | |||||||||
Personnel Remuneration | Personnel Remuneration | |||||||||||||||||||||
7 | Abbott India Limited | AAACB5170B | Rajiv Sonalker | ZZZZZ9999Z | KMP - Whole-Time | Key Management | Key Management | NA | Approved | 2.57 | 0 | 0 | - | |||||||||
Director | Personnel Remuneration | Personnel Remuneration | ||||||||||||||||||||
8 | Abbott India Limited | AAACB5170B | Abbott India Limited Officers' Group | ZZZZZ9999Z | Other related party | Contributions made to | Contributions made to | 9 | Approved | 3.97 | 0 | 0 | - | |||||||||
Gratuity Scheme | Employee Benefit Funds | Employee Benefit Funds | ||||||||||||||||||||
9 | Abbott India Limited | AAACB5170B | Abbott India Ltd Employees' Group | ZZZZZ9999Z | Other related party | Contributions made to | Contributions made to | 1.5 | Approved | 1.06 | 0 | 0 | - | |||||||||
Gratuity-cum-Life Assurance Scheme | Employee Benefit Funds | Employee Benefit Funds | ||||||||||||||||||||
10 | Abbott India Limited | AAACB5170B | Abbott India Ltd (Solvay Pharma India | ZZZZZ9999Z | Other related party | Contributions made to | Contributions made to | 1.5 | Approved | 1.92 | 0 | 0 | - | Excess value of actual | ||||||||
Pvt Ltd) Employees' Group Gratuity | Employee Benefit Funds | Employee Benefit Funds | transaction amounting to Rs | |||||||||||||||||||
Scheme | 0.42 Crore is approved and | |||||||||||||||||||||
ratified by the Audit | ||||||||||||||||||||||
Committee at its Meeting | ||||||||||||||||||||||
held on May 19, 2023 | ||||||||||||||||||||||
11 | Abbott India Limited | AAACB5170B | Abbott Diagnostics Medical Private | AABCS2425B | Fellow Subsidiary | Shared and Support | Shared and Support | 0.3 | Approved | 0.19 | 0.05 | 0.09 | - | |||||||||
Limited, India | Service Income | Service Income | ||||||||||||||||||||
12 | Abbott India Limited | AAACB5170B | Abbott Healthcare Private Limited, India | AAACK3935D | Fellow Subsidiary | Purchase of goods or | Purchase of goods or | 29 | Approved | 18.02 | 9.74 | 8.72 | - | |||||||||
services | services | |||||||||||||||||||||
13 | Abbott India Limited | AAACB5170B | Abbott Healthcare Private Limited, India | AAACK3935D | Fellow Subsidiary | Purchase of goods or | Purchase of goods or | 1 | Approved | 0.27 | 0 | 0 | - | |||||||||
services | services | |||||||||||||||||||||
14 | Abbott India Limited | AAACB5170B | Abbott Healthcare Private Limited, India | AAACK3935D | Fellow Subsidiary | Loan Licence charges | Loan Licence charges | 14 | Approved | 6.32 | 0 | 0 | - | |||||||||
15 | Abbott India Limited | AAACB5170B | Abbott Healthcare Private Limited, India | AAACK3935D | Fellow Subsidiary | Reimbursement of | Reimbursement of | 30 | Approved | 27.99 | 4.76 | 0 | ||||||||||
expenses | expenses | |||||||||||||||||||||
16 | Abbott India Limited | AAACB5170B | Abbott Healthcare Private Limited, India | AAACK3935D | Fellow Subsidiary | Reimbursement of | Reimbursement of | 20 | Approved | 16.61 | 0 | 0 | - | |||||||||
expenses | expenses | |||||||||||||||||||||
17 | Abbott India Limited | AAACB5170B | Abbott Healthcare Private Limited, India | AAACK3935D | Fellow Subsidiary | Reimbursement of | Reimbursement of | 1 | Approved | 0.48 | 0 | 0 | ||||||||||
expenses | expenses | |||||||||||||||||||||
18 | Abbott India Limited | AAACB5170B | Abbott Healthcare Private Limited, India | AAACK3935D | Fellow Subsidiary | Sale of goods or services | Sale of goods or services | 36 | Approved | 25.84 | 12.68 | 7.9 | ||||||||||
19 | Abbott India Limited | AAACB5170B | Abbott Healthcare Private Limited, India | AAACK3935D | Fellow Subsidiary | Sale of goods or services | Sale of goods or services | 5.3 | Approved | 1.07 | 0 | 0 | ||||||||||
20 | Abbott India Limited | AAACB5170B | Abbott Healthcare Private Limited, India | AAACK3935D | Fellow Subsidiary | Shared and Support | Shared and Support | 30 | Approved | 25.58 | 4.06 | 0.43 | ||||||||||
Service Income | Service Income | |||||||||||||||||||||
21 | Abbott India Limited | AAACB5170B | Abbott Healthcare Private Limited, India | AAACK3935D | Fellow Subsidiary | Reimbursement of | Reimbursement of | 0.8 | Approved | 0.45 | 0 | 0 | - | |||||||||
expenses | expenses | |||||||||||||||||||||
22 | Abbott India Limited | AAACB5170B | Abbott Healthcare Private Limited, India | AAACK3935D | Fellow Subsidiary | Reimbursement of | Reimbursement of | 0.2 | Approved | 0.12 | 0 | 0 | - | |||||||||
expenses | expenses | |||||||||||||||||||||
23 | Abbott India Limited | AAACB5170B | Abbott International LLC, USA | ZZZZZ9999Z | Fellow Subsidiary | Reimbursement of | Reimbursement of | 1 | Approved | 0.1 | 0 | 0.1 | - | |||||||||
expenses | expenses | |||||||||||||||||||||
24 | Abbott India Limited | AAACB5170B | Abbott International LLC, USA | ZZZZZ9999Z | Fellow Subsidiary | Reimbursement of | Reimbursement of | 0.2 | Approved | 0 | 0 | 4.19 | - | |||||||||
expenses | expenses | |||||||||||||||||||||
25 | Abbott India Limited | AAACB5170B | Abbott Laboratories (Singapore) Pte | ZZZZZ9999Z | Fellow Subsidiary | Reimbursement of | Reimbursement of | 1 | Approved | 0.05 | 0.32 | 0.05 | ||||||||||
Limited, Singapore | expenses | expenses | ||||||||||||||||||||
26 | Abbott India Limited | AAACB5170B | Abbott Laboratories (Singapore) Pte | ZZZZZ9999Z | Fellow Subsidiary | Reimbursement of | Reimbursement of | 1 | Approved | 1.16 | 0.17 | 0.29 | Excess value of actual | |||||||||
Limited, Singapore | expenses | expenses | transaction amounting to Rs | |||||||||||||||||||
0.16 Crore is approved and | ||||||||||||||||||||||
ratified by the Audit | ||||||||||||||||||||||
Committee at its Meeting | ||||||||||||||||||||||
held on May 19, 2023 | ||||||||||||||||||||||
27 | Abbott India Limited | AAACB5170B | Abbott Laboratories GmbH, UAE | ZZZZZ9999Z | Fellow Subsidiary | Reimbursement of | Reimbursement of | 1 | Approved | 1.17 | 0.17 | 0.29 | Excess value of actual | |||||||||
expenses | expenses | transaction amounting to Rs | ||||||||||||||||||||
0.17 Crore is approved and | ||||||||||||||||||||||
ratified by the Audit | ||||||||||||||||||||||
Committee at its Meeting | ||||||||||||||||||||||
held on May 19, 2023 | ||||||||||||||||||||||
28 | Abbott India Limited | AAACB5170B | Abbott Laboratories Limited, Thailand | ZZZZZ9999Z | Fellow Subsidiary | Reimbursement of | Reimbursement of | 0.5 | Approved | 0 | 0.18 | 0 | ||||||||||
expenses | expenses | |||||||||||||||||||||
29 | Abbott India Limited | AAACB5170B | Abbott Laboratories, USA | ZZZZZ9999Z | Ultimate Holding | Reimbursement of | Reimbursement of | 20 | Approved | 12.14 | 0 | 0 | ||||||||||
Company | expenses | expenses | ||||||||||||||||||||
30 | Abbott India Limited | AAACB5170B | Abbott Laboratories, USA | ZZZZZ9999Z | Ultimate Holding | Reimbursement of | Reimbursement of | 5 | Approved | 2.91 | 0 | 1.48 | ||||||||||
Company | expenses | expenses | ||||||||||||||||||||
31 | Abbott India Limited | AAACB5170B | Abbott Products Operations AG. | ZZZZZ9999Z | Fellow Subsidiary | Purchase of goods or | Purchase of goods or | 74 | Approved | 59.54 | 138.04 | 124.09 | ||||||||||
Switzerland | services | services | ||||||||||||||||||||
32 | Abbott India Limited | AAACB5170B | Abbott Products Operations AG. | ZZZZZ9999Z | Fellow Subsidiary | Purchase of goods or | Purchase of goods or | 246 | Approved | 156.37 | 0 | 0 | ||||||||||
Switzerland | services | services | ||||||||||||||||||||
33 | Abbott India Limited | AAACB5170B | Abbott Products Operations AG. | ZZZZZ9999Z | Fellow Subsidiary | Shared and Support | Shared and Support | 5 | Approved | 2.98 | 0.4 | 0.67 | ||||||||||
Switzerland | Service Income | Service Income | ||||||||||||||||||||
34 | Abbott India Limited | AAACB5170B | Abbott Products Operations AG. | ZZZZZ9999Z | Fellow Subsidiary | Sale of goods or services | Sale of goods or services | 1 | Approved | 0.92 | 0 | 0.35 | ||||||||||
Switzerland | ||||||||||||||||||||||
35 | Abbott India Limited | AAACB5170B | Abbott Laboratuarlari Ithalat Ve Ihracat | ZZZZZ9999Z | Fellow Subsidiary | Reimbursement of | Reimbursement of | 0 | Approved | 0.01 | 0 | 0 | Excess value of actual | |||||||||
Tic.Ltd.Sti. | expenses | expenses | transaction amounting to Rs | |||||||||||||||||||
0.01 Crore is approved and | ||||||||||||||||||||||
ratified by the Audit | ||||||||||||||||||||||
Committee at its Meeting | ||||||||||||||||||||||
held on May 19, 2023 | ||||||||||||||||||||||
36 | Abbott India Limited | AAACB5170B | St. Jude Medical India Private Limited, | AAICS9821J | Fellow Subsidiary | Shared and Support | Shared and Support | 2 | Approved | 0.61 | 0.11 | 0.11 | ||||||||||
India | Service Income | Service Income | ||||||||||||||||||||
37 | Abbott India Limited | AAACB5170B | Anisha Motwani | ZZZZZ9999Z | Independent Director | Annual fixed Commission | Annual fixed Commission | NA | Approved | 0.15 | 0 | 0 | ||||||||||
38 | Abbott India Limited | AAACB5170B | Kaiyomarz Marfatia | ZZZZZ9999Z | Non-Executive Director | Annual fixed Commission | Annual fixed Commission | NA | Approved | 0.15 | 0 | 0 | ||||||||||
39 | Abbott India Limited | AAACB5170B | Munir Shaikh | ZZZZZ9999Z | Non-Executive Director | Annual fixed Commission | Annual fixed Commission | NA | Approved | 0.2 | 0 | 0 | ||||||||||
40 | Abbott India Limited | AAACB5170B | Shalini Kamath | ZZZZZ9999Z | Independent Director | Annual fixed Commission | Annual fixed Commission | NA | Approved | 0.15 | 0 | 0 | ||||||||||
41 | Abbott India Limited | AAACB5170B | Sudarshan Jain | ZZZZZ9999Z | Independent Director | Annual fixed Commission | Annual fixed Commission | NA | Approved | 0.15 | 0 | 0 | ||||||||||
537.3 | 376.2 | 170.68 | 148.76 | - | ||||||||||||||||||
Total | ||||||||||||||||||||||
* Outstanding balances are balances as on date and but not due |
KRUPA
KETAN ANANDPARA
Digitally signed by
KRUPA KETAN
ANANDPARA Date: 2023.05.19 19:25:01 +05'30'
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Abbott India Limited published this content on 19 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 May 2023 16:33:54 UTC.
